JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online May 14, 2009, 10.2967/jnumed.108.061457
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow All Versions of this Article:
jnumed.108.061457v1
50/6/936    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waser, B.
Right arrow Articles by Reubi, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waser, B.
Right arrow Articles by Reubi, J. C.
Journal of Nuclear Medicine Vol. 50 No. 6 936-941
© 2009 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.061457

Basic Science Investigation

Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues

Bea Waser1, Maria-Luisa Tamma2, Renzo Cescato1, Helmut R. Maecke2 and Jean Claude Reubi1

1 Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; and 2 Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland

Correspondence: For correspondence or reprints contact: Jean Claude Reubi, Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, P.O. Box 62, Murtenstrasse 31, CH-3010 Berne, Switzerland. E-mail: reubi{at}pathology.unibe.ch

The successful peptide receptor imaging of tumors, as exemplified for somatostatin receptors, is based on the overexpression of peptide receptors in selected tumors and the high-affinity binding to these tumors of agonist radioligands that are subsequently internalized into the tumor cells in which they accumulate. Although in vitro studies have shown ample evidence that the ligand–receptor complex is internalized, in vivo evidence of agonist-induced internalization of peptide receptors, such as somatostatin receptors, is missing. Methods: Rats subcutaneously transplanted with the somatostatin receptor subtype 2 (sst2)–expressing AR42J tumor cells were treated with intravenous injections of various doses of the sst2 agonist [Tyr3, Thr8]-octreotide (TATE) or of the sst2 antagonist 1,4,7,10-tetraazacyclododecane-N,N',N'',N''',-tetraacetic acid (DOTA)-Bass and were sacrificed at various times ranging from 2.5 min to 24 h after injection. The tumors and pancreas were then removed from each animal. All tissue samples were processed for sst2 immunohistochemistry using sst2-specific antibodies. Results: Compared with the sst2 receptors in untreated animals, which localized at the plasma membrane in pancreatic and AR42J tumor cells, the sst2 receptors in treated animals are detected intracellularly after an intravenous injection of the agonist TATE. Internalization is fast, as the receptors are already internalizing 2.5 min after TATE injection. The process is extremely efficient, as most of the cell surface receptors internalize into the cell and are found in endosomelike structures after TATE injection. The internalization is most likely reversible, because 24 h after injection the receptors are again found at the cell surface. The process is also agonist-dependent, because internalization is seen with high-affinity sst2 agonists but not with high-affinity sst2 antagonists. The same internalization properties are seen in pancreatic and AR42J tumor cells. They can further be confirmed in vitro in human embryonic kidney–sst2 cells, with an immunofluorescence microscopy–based sst2 internalization assay. Conclusion: These animal data strongly indicate that the process of in vivo sst2 internalization after agonist stimulation is fast, extremely efficient, and fully functional under in vivo conditions in neoplastic and physiologic sst2 target tissues. This molecular process is, therefore, likely to be responsible for the high and long-lasting uptake of sst2 radioligands seen in vivo in sst2-expressing tumors.

Key Words: peptide receptor targeting • somatostatin receptor • in vivo internalization • tumor imaging • neuropeptides

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.